Logo Université Laval Logo Université Laval
International Chair on Cardiometabolic Risk
My Healthy Waist

Documentation centre

2497-2508 of 2541 results
Page 209 of 212
Key Publications July 31, 2008

Action to Control Cardiovascular Risk in Diabetes Study Group, Effects of intensive glucose lowering in type 2 diabetes.

N Engl J Med 2008;358:2545-59

Gerstein HC, Miller ME, Byington RP et al.
Cardiovascular Disease Diabetes Insulin Resistance
Key Publications July 31, 2008

ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

N Engl J Med 2008;358:2560-72

Patel A, MacMahon S, Chalmers J et al.
Cardiovascular Disease Diabetes Insulin Resistance
Key Publications July 10, 2008

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.

JAMA 2008;299:1265-76

Bhattacharyya T, Nicholls SJ, Topol EJ et al.
Cardiovascular Disease Genetics
Key Publications July 9, 2008

Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.

Metabolism 2008;57:796-801

Tribble DL, Farnier M, Macdonell G et al.
Cardiovascular Disease Lipids/Lipoproteins Prevention
Key Publications June 24, 2008

Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.

Arterioscler Thromb Vasc Biol 2008;28:1172-8

Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF
Cardiovascular Disease Lipids/Lipoproteins Prevention
Key Publications June 18, 2008

Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden.

Circulation 2008;117:2458-66

Ballantyne CM, Raichlen JS, Nicholls SJ et al.
Cardiovascular Disease Interventional Cardiology Lipids/Lipoproteins
Key Publications June 7, 2008

The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.

J Am Coll Cardiol 2008;51:1653-62

Ky B, Burke A, Tsimikas S et al.
Cardiovascular Disease Lipids/Lipoproteins Metabolism: Human Studies
Key Publications June 5, 2008

Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy.

Eur Heart J 2008;29:1168-80

Skurk C, Wittchen F, Suckau L et al.
Adipokines Cardiovascular Disease Inflammation
Key Publications June 4, 2008

Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries.

Diabetes Care 2008;31:989-94

Marso SP, Mehta SK, Frutkin A, House JA, McCrary JR, Kulkarni KR
Adipokines Cardiovascular Disease Lipids/Lipoproteins
Key Publications May 28, 2008

An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma.

J Lipid Res 2008;49:581-7

Troutt JS, Alborn WE, Mosior MK et al.
Cardiovascular Disease Lipids/Lipoproteins Metabolism
Key Publications May 28, 2008

Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.

Atherosclerosis 2008;197:355-62

Schuster H, Fagerberg B, Edwards S et al.
Cardiovascular Disease Insulin Resistance Lipids/Lipoproteins
Key Publications May 22, 2008

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.

J Am Coll Cardiol 2008;51:1448-54

Shepherd J, Kastelein JJ, Bittner V et al.
Cardiovascular Disease Lipids/Lipoproteins Prevention
of 212